Capell · Proceedings of the National Academy of Sciences of the United States of America 2005 · In vitro controlled laboratory experiment · n=?

Inhibiting farnesylation of progerin prevents the characteristic nuclear blebbing of Hutchinson-Gilford progeria syndrome.

Cited 391 times in the scientific literature.

Level 5 - mechanism / opinion, no new human data

Preclinical in vitro bench research in cell lines and patient-derived fibroblasts.

PubMed 16129833 · doi:10.1073/pnas.0506001102 · record verified 2026-08-30

What was done

Researchers investigated whether blocking the farnesylation of progerin (a mutant, truncated prelamin A protein) prevents cellular toxicity and nuclear envelope deformation in Hutchinson-Gilford progeria syndrome (HGPS). They genetically altered progerin's farnesylation site (CSIM mutated to non-farnesylated SSIM) and treated progerin-transfected cell lines (HeLa, HEK 293, NIH 3T3) and cultured human HGPS fibroblasts (early- and late-passage) with farnesyltransferase inhibitors (FTIs). Nuclear architecture and blebbing were assessed.

What was found

Mutating the farnesylation target sequence (SSIM progerin) caused progerin to relocalize from the nuclear periphery into nucleoplasmic aggregates and eliminated nuclear blebbing. Pharmacological inhibition of farnesylation via FTIs restored normal nuclear architecture in transiently transfected HeLa, HEK 293, and NIH 3T3 cells, and led to significant reductions in nuclear blebbing in both early- and late-passage human HGPS fibroblasts. The abstract provides directional findings without quantitative metrics or effect sizes.

Why it matters

This study provides preclinical mechanistic proof-of-concept that blocking progerin farnesylation with FTIs can reverse cellular nuclear envelope abnormalities, establishing the foundational rationale for using FTIs as a potential targeted therapy for Hutchinson-Gilford progeria syndrome.

Limits

This was an in vitro cell culture study evaluating nuclear morphology; it did not assess in vivo efficacy, systemic pharmacokinetics, survival, or cardiovascular outcomes in animal models or human patients. The abstract reports no exact numerical values or sample counts (n).

Cited by